NHMRC provides assistance to Australian researchers to participate in collaborative research projects with international researchers through both bilateral and multilateral arrangements.
To participate in these schemes, your personal information may need to be disclosed by NHMRC to overseas recipients, generally for the purposes of peer review of the application. You will be advised of this possibility at the time of making your application.
For further information on open calls for research with NHMRC’s international partners, please refer to the Find Funding page of the website.
UK Research and Innovation
The UK’s Fund for International Collaboration (FIC) aims to enhance excellence in research and innovation through global engagement. It focuses on bilateral and multilateral partnerships with global research and development leaders and is administered by UK Research and Innovation (UKRI) which includes the Medical Research Council (MRC) and Economic and Social Research Council (ESRC).
NHMRC and the MRC signed a Memorandum of Understanding in May 2019 to promote and encourage collaboration between Australia and the UK in world-leading prevention research seeking to address the shared burden of non-communicable diseases (NCDs) influenced by the built environment.
NHMRC is providing up to $4 million of funding to support Australian researchers participating in the joint UKRI-NHMRC Build Environment and Prevention Research Scheme 2019 Grant Opportunity.
e-ASIA Joint Research Program
The e-ASIA Joint Research Program (JRP) was established in 2012 to promote innovation and contribute to economic development in the East Asian region. e-ASIA aims to achieve this by formulating and supporting international joint research projects in the East Asian region on a multilateral basis as well as promoting researcher interaction through workshops.
NHMRC became a member organisation of JRP on 2 November 2016. NHMRC’s CEO represents NHMRC on the e-ASIA JRP Board.
Find out more about NHMRC’s participation in the e-ASIA JRP health research 8th joint call for funding in 2019.
For further information refer to the e-ASIA JRP website.
European Union Joint Programme – Neurodegenerative Disease Research (JPND)
The European Union Joint Programme – Neurodegenerative Disease Research (JPND) is a large global research initiative aimed at tackling the challenge of neurodegenerative diseases. JPND aims to increase coordinated investment between participating countries in research aimed at finding causes, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases.
The ultimate goal of JPND is to find cures for neurodegenerative diseases and to enable early diagnosis for early targeted treatments.
For further information refer to the JPND website.
Global Alliance for Chronic Diseases (GACD)
NHMRC is part of the Global Alliance for Chronic Diseases (GACD). NHMRC’s CEO is a member of the Board and has been elected Chair for 2019 and 2020.
The GACD funds, develops and facilitates innovative research collaborations between low, middle and high income countries in the fight against chronic diseases.
For current status, further information and funding outcomes refer to Global Alliance for Chronic Diseases (GACD).
The GACD has launched a new promotional video, highlighting the need for coordinated global research funding to tackle the ever-growing burden of chronic diseases worldwide. The video is available on YouTube.
Human Frontier Science Program (HFSP)
The Human Frontier Science Program (HFSP) is an international organisation funding frontier research on the complex mechanisms of living organisms. Research is funded at all levels of biological complexity from biomolecules to the interactions between organisms.
Australia is a member of the HFSP through a formal Government agreement.
The HFSP is funded by contributions from the EU and 13 other countries, including Australia.
This program is not administered by the NHMRC. Interested parties should refer to the HFSP website for definitive information on this program.
International Cancer Genome Consortium (ICGC)
The International Cancer Genome Consortium (ICGC) has been organised to launch and coordinate research projects that have the common aim of elucidating the genomic changes present in many forms of cancers that contribute to the burden of disease throughout the world.
The aim is to obtain a comprehensive description of the full range of genetic events associated with these tumour types and make the data available to the entire research community as rapidly as possible, and with minimal restrictions, to accelerate research into the causes, diagnosis and control of cancer.
Countries participating in the ICGC include Australia, Canada, China, India, Singapore, the United Kingdom, the United States and many European nations.
There are now 18 countries involved with ICGC, the database has over 20,000 donor samples and over 57,000 mutated genes analysed.
The next phase of ICGC focuses on the Pan Cancer Analysis of Whole Genomes (PCAWG), defines similarities and differences between cancer types. Previously, the consortium explored Accelerating Research in Genomic Oncology (ICGC-ARGO) where key clinical questions and patient clinical data drive the interrogation of cancer genomes. NHMRC recognises the value of ICGC and remains on the ICGC Executive and Scientific Steering Committees.
National Foundation for Science and Technology Development of Vietnam (NAFOSTED)
NAFOSTED was established in 2008 and functions as a not-for-profit funder in scientific and technological research projects. NAFOSTED is affiliated with Vietnam’s Ministry for Science and Technology.
NHMRC and NAFOSTED signed a Memorandum of Understanding in December 2015 to promote and encourage international health and medical research collaboration between Australia and Vietnam. A joint symposium was held in Hanoi, Vietnam in November 2016.
NHMRC and NAFOSTED have developed a joint call to support international collaboration between Vietnam and Australia and to generate new knowledge in the three research areas of Infectious Diseases, Maternal/Child Health, and Public Health. The NHMRC/NAFOSTED Joint Call for Collaborative Research opened for applications 6 December 2017 and closed 14 March 2018.
For outcomes of the joint symposium please refer to: 2016 NAFOSTED-NHMRC Joint Networking Symposium for Health and Medical Researchers.
For outcomes of the NHMRC/NAFOSTED Joint Call for Collaborative Research please refer to: Outcomes of funding rounds.
National Institutes of Health (NIH)-BRAIN
The NHMRC–NIH BRAIN scheme provides a contribution to Australian institutions and researchers who are participating in leading international collaborative research that has been selected for funding through the NIH BRAIN Initiative. The BRAIN Initiative is intended to revolutionise understanding of the human brain. The aim of the initiative is to accelerate the development and application of innovative technologies to assist researchers to produce a revolutionary new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.
For current status, further information and funding outcomes refer to: NHMRC–NIH BRAIN Initiative Collaborative Research Grants.
National Institute for Health Research (NIHR)
The mission of the United Kingdom’s National Institute for Health Research (NIHR) is to maintain a health research system in which the NHS supports outstanding individuals, working in world class facilities, conducting leading edge research focused on the needs of patients and the public.
In August 2013, NHMRC signed a Memorandum of Understanding (MOU) with the NIHR to co-fund collaborative clinical trials with both an Australian and UK component.
NHMRC – EU Collaborative Research Grant scheme
The NHMRC‒European Union Collaborative Research Grants scheme supports Australian participation in leading international collaborative research under the EU Framework Programme. The Framework Programme is the EU’s main instrument for funding research and development.
In 2014 the EU implemented its new funding instrument Horizon 2020.